Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma

J Surg Oncol. 2021 May;123(6):1432-1440. doi: 10.1002/jso.26384.

Abstract

For patients with localized pancreatic cancer, neoadjuvant therapy (NT) is increasingly delivered before surgery to maximize the receipt of multimodality therapy and the odds of a margin-negative resection. Three decades of refining the use of NT have led to its acceptance as a valid treatment approach for pancreatic adenocarcinoma. In this review, we discuss the rationale for and recent global trends in the utilization of NT for patients with pancreatic cancer.

Keywords: FOLFIRINOX; neoadjuvant chemotherapy; pancreatic cancer; pancreatoduodenectomy; preoperative therapy; whipple.

Publication types

  • Review

MeSH terms

  • Albumins / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / radiotherapy
  • Carcinoma, Pancreatic Ductal / surgery
  • Carcinoma, Pancreatic Ductal / therapy*
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Fluorouracil / administration & dosage
  • Gemcitabine
  • Humans
  • Irinotecan / administration & dosage
  • Leucovorin / administration & dosage
  • Neoadjuvant Therapy
  • Oxaliplatin / administration & dosage
  • Paclitaxel / administration & dosage
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / radiotherapy
  • Pancreatic Neoplasms / surgery
  • Pancreatic Neoplasms / therapy*
  • Randomized Controlled Trials as Topic

Substances

  • 130-nm albumin-bound paclitaxel
  • Albumins
  • folfirinox
  • Oxaliplatin
  • Deoxycytidine
  • Irinotecan
  • Paclitaxel
  • Leucovorin
  • Fluorouracil
  • Gemcitabine